Why health insurance stocks plunged: CMS proposal signals just a 0.09% Medicare Advantage payment increase for 2027

Health insurance stocks dropped sharply Tuesday after the Centers for Medicare and Medicaid Services (CMS) proposed a much smaller-than-expected increase in Medicare Advantage payment rates for 2027. The proposed average bump—about 0.09%—was a shock to investors who had been anticipating several percentage points of growth based on prior years and Wall Street estimates.

The selling was broad and fast. UnitedHealth, Humana and CVS Health were among the biggest decliners as traders repriced 2027 profitability. Medicare Advantage is a core earnings engine for many insurers, and even a modest change in reimbursement trends can ripple through benefits design, provider contracting, and the ability to maintain margins without cutting services.

CMS’s proposal also includes technical changes around diagnostic coding, a particularly sensitive issue because diagnoses influence risk scores that help determine payments. The proposal comes amid a climate of tougher oversight and public reporting around Medicare Advantage practices, adding to fears that earnings recovery in the group could take longer than investors had hoped.

In practical terms, insurers may face a menu of unattractive options if the proposal holds: reduce plan extras such as supplemental benefits, raise premiums, narrow networks, pull back in certain counties, or attempt operational cost reductions. None of those moves are painless, especially in a competitive market where companies fight to retain seniors with rich benefits and low out-of-pocket costs.

The proposal is not final, and the industry is expected to push back during the comment process. Still, the market reaction illustrates how tightly the sector is tied to Washington’s policy decisions—and how quickly sentiment can shift when the reimbursement outlook changes by even a few percentage points.

For consumers, the stakes could show up later in plan availability and benefit generosity for 2027, depending on where rates settle. For investors, the message was immediate: Medicare Advantage policy risk is once again the dominant variable for the group, and it may remain so until the government releases a final rate notice.